INmune Bio Expands CORDStrom Collaboration with Anthony Nolan, Securing Long-Term Cord Supply for RDEB, Oncology and Inflammation
INmune Bio has signed an amended Material Transfer and License Agreement with Anthony Nolan, effective April 29, 2026, securing long-term umbilical cord tissue supply for its CORDStrom MSC platform across UK, EU and US. The collaboration targets RDEB, oncology through CORDStrom-TRAIL, osteoarthritis and SLE using standardized pooled hucMSC banks.
1. Agreement Expansion and Terms
The amended and restated Material Transfer and License Agreement between INmune Bio and Anthony Nolan, effective April 29, 2026, secures the long-term supply of high-quality umbilical cord tissue under GMP and HTA standards. The contract includes rigorous traceability, quality management provisions and supports global regulatory oversight across UK, EU and US markets.
2. CORDStrom Platform Advantages
The CORDStrom MSC platform addresses donor variability and manufacturing inconsistency by pooling and screening umbilical cord-derived MSCs to create standardized cell banks. Anthony Nolan’s screening infrastructure ensures each batch meets precise neonatal weight and maternal age criteria, enhancing reproducibility and potency for off-the-shelf cell therapies.
3. Targeted Indications and Pipeline
Initial development focuses on CORDStrom-col7a for Recessive Dystrophic Epidermolysis Bullosa, CORDStrom-TRAIL for solid tumors and inflammatory indications such as osteoarthritis and systemic lupus erythematosus. This expanded collaboration positions INmune Bio to advance these candidates through clinical development and eventual commercial approval.